North American Operations Management Team

Fabio Piazzalunga
President & Chief Executive Officer

Ana Aguilar
Chief Financial Officer

Mark Connelly
Chief Research & Development Officer

Karen Davis-Fleischer
Vice President, Commercial, North America

John Clay
Vice President, Quality Assurance & Regulatory Affairs

*Metastatic prostate cancer patients were defined as having two consecutive increases in the serum marker prostate-specific antigen above a reference level, despite standard hormonal management. These patients are commonly described as having androgen-independent, hormone-resistant, or castration-resistant prostate cancer. For more information on the intended use and limitations for the CELLSEARCH® Circulating Tumor Cell Test, please refer to the Instructions for Use which can be found at documents.cellsearchctc.com.